Hepatic Krüppel‐like factor 14 regulates lipid metabolism in nonalcoholic steatohepatitis mice
暂无分享,去创建一个
Xuan Xu | Hui Liu | Xiao-Yuu Chen | Yunwu Wang | Wenjie Shi | Huajing Ke | Qian Yao | Ping-Ping Liu | Xiaojiang Zhou | Yongtao Xie
[1] K. Cusi,et al. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. , 2022, The lancet. Diabetes & endocrinology.
[2] Weixuan Wang,et al. Breviscapine alleviates NASH by inhibiting TGF‐β‐activated kinase 1‐dependent signaling , 2021, Hepatology.
[3] Shaoping Huang,et al. Nobiletin mitigates hepatocytes death, liver inflammation, and fibrosis in a murine model of NASH through modulating hepatic oxidative stress and mitochondrial dysfunction. , 2021, The Journal of nutritional biochemistry.
[4] H. Tilg,et al. Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. , 2021, The lancet. Gastroenterology & hepatology.
[5] P. Caravan,et al. Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis , 2021, Scientific Reports.
[6] Y. E. Chen,et al. Krüppel-Like Factor 14 Deletion In Myeloid Cells Accelerates Atherosclerotic Lesion Development. , 2021, Cardiovascular research.
[7] Yongsheng Chang,et al. Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance , 2020, Gut.
[8] K. Miyashita,et al. Fucoxanthin inhibits hepatic oxidative stress, inflammation, and fibrosis in diet-induced nonalcoholic steatohepatitis model mice. , 2020, Biochemical and biophysical research communications.
[9] B. Neuschwander‐Tetri. Therapeutic landscape for NAFLD in 2020. , 2020, Gastroenterology.
[10] Heng Zhang,et al. The role of KLF14 in multiple disease processes , 2020, BioFactors.
[11] Xi-Long Zheng,et al. Krüppel-like factor 14 inhibits atherosclerosis via mir-27a-mediated down-regulation of lipoprotein lipase expression in vivo. , 2019, Atherosclerosis.
[12] T. Uchida,et al. Histological evaluation of nintedanib in non-alcoholic steatohepatitis mice. , 2019, Life sciences.
[13] Wei Ma,et al. Dexamethasone-induced Krüppel-like factor 9 expression promotes hepatic gluconeogenesis and hyperglycemia. , 2019, The Journal of clinical investigation.
[14] H. Hermanns,et al. Animal models of NAFLD from a hepatologist's point of view. , 2019, Biochimica et biophysica acta. Molecular basis of disease.
[15] T. Ishikawa,et al. Vitronectin deficiency attenuates hepatic fibrosis in a non‐alcoholic steatohepatitis‐induced mouse model , 2019, International journal of experimental pathology.
[16] Z. Younossi. Non-alcoholic fatty liver disease - A global public health perspective. , 2019, Journal of hepatology.
[17] F. Tacke,et al. Macrophages in obesity and non-alcoholic fatty liver disease: Crosstalk with metabolism , 2019, JHEP reports : innovation in hepatology.
[18] Xiaoyan Chen,et al. Overexpression of KLF14 protects against immune-mediated hepatic injury in mice , 2018, Laboratory Investigation.
[19] Andrew R. Hall,et al. CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis. , 2018, Journal of hepatology.
[20] B. Neuschwander‐Tetri,et al. Mechanisms of NAFLD development and therapeutic strategies , 2018, Nature Medicine.
[21] O. Ilkayeva,et al. Kruppel-like factor 15 is required for the cardiac adaptive response to fasting , 2018, PloS one.
[22] M. Eslam,et al. Genetics and epigenetics of NAFLD and NASH: Clinical impact. , 2018, Journal of hepatology.
[23] Huabing Zhang,et al. The KLF14 transcription factor regulates hepatic gluconeogenesis in mice , 2017, The Journal of Biological Chemistry.
[24] Huabing Zhang,et al. KLF10 transcription factor regulates hepatic glucose metabolism in mice , 2017, Diabetologia.
[25] P. He,et al. SP and KLF Transcription Factors in Digestive Physiology and Diseases. , 2017, Gastroenterology.
[26] Jun Yu,et al. Animal models of non‐alcoholic fatty liver disease: current perspectives and recent advances , 2016, The Journal of pathology.
[27] Y. Rotman,et al. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease , 2016, Gut.
[28] Tingting Zhou,et al. Krüppel-like factor 14 increases insulin sensitivity through activation of PI3K/Akt signal pathway. , 2015, Cellular signalling.
[29] D. Rader,et al. Perhexiline activates KLF14 and reduces atherosclerosis by modulating ApoA-I production. , 2015, The Journal of clinical investigation.
[30] Douglas A. Simonetto,et al. New Role for Kruppel-like Factor 14 as a Transcriptional Activator Involved in the Generation of Signaling Lipids* , 2014, The Journal of Biological Chemistry.
[31] S. Kersten. Integrated physiology and systems biology of PPARα , 2014, Molecular metabolism.
[32] Saptarsi M. Haldar,et al. Kruppel-like Factor 15 Is a Critical Regulator of Cardiac Lipid Metabolism* , 2014, The Journal of Biological Chemistry.
[33] D. Hum,et al. Hepatoprotective effects of the dual peroxisome proliferator‐activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis , 2013, Hepatology.
[34] Marie-Pier Tétreault,et al. Krüppel-like factors in cancer , 2013, Nature Reviews Cancer.
[35] Min Wang,et al. Mouse KLF11 regulates hepatic lipid metabolism. , 2013, Journal of hepatology.
[36] C. Tanaka,et al. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis , 2013, International journal of experimental pathology.
[37] L. Jin,et al. Genome‐wide association study validation identifies novel loci for atherosclerotic cardiovascular disease , 2012, Journal of thrombosis and haemostasis : JTH.
[38] Jiansheng Huang,et al. Sustained activation of PPARα by endogenous ligands increases hepatic fatty acid oxidation and prevents obesity in ob/ob mice , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[39] T. Spector,et al. Corrigendum: Identification of an imprinted master trans regulator at the KLF14 locus related to multiple metabolic phenotypes , 2011, Nature Genetics.
[40] Mark I. McCarthy,et al. Identification of an imprinted master trans-regulator at the KLF14 locus related to multiple metabolic phenotypes , 2011, Nature Genetics.
[41] F. Gonzalez,et al. PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver. , 2011, The Journal of nutrition.
[42] V. Yang,et al. Mammalian Krüppel-like factors in health and diseases. , 2010, Physiological reviews.
[43] R. Urrutia,et al. Sp1- and Krüppel-like transcription factors , 2003, Genome Biology.
[44] Xiaobin Pang,et al. Luteoloside attenuates neuroinflammation in focal cerebral ischemia in rats via regulation of the PPAR&ggr;/Nrf2/NF‐&kgr;B signaling pathway , 2019, International immunopharmacology.
[45] A. Diehl,et al. Animal Models of Nonalcoholic Fatty Liver Disease , 2016 .
[46] Jack A. Taylor,et al. Supplementary file 1. , 2014 .
[47] Joseph P. Near,et al. How to cite this article , 2011 .
[48] F. Schaffner,et al. Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.